Emmaus’ lead candidate is an oral pharmaceutical grade L-glutamine treatment that demonstrated positive clinical results in a completed Phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia. The therapy has Orphan Drug designation in the U.S. and Europe, and also received Fast Track designation from the FDA.